Skip to main content

Message from David Pidduck, President and CEO: ADHD Awareness Month

Published on - October 2, 2018

ADHD is a neurobiological disorder that is often hereditary and results in difficulty regulating attention,…

Read More >

BETADINE® – A NEW TREATMENT OPTION FOR CANADIANS FOR ORAL INFECTIONS – NOW AVAILABLE IN CANADA

Published on - September 4, 2018

PICKERING, ON, September 4, 2018 – Purdue Pharma (Canada) announces today that BETADINE® Sore Throat…

Read More >

Cancer Survivor Month – Message from Melanie Milburn, Vice President Marketing

Published on - June 1, 2018

This June, Purdue Pharma (Canada) joins all of those celebrating Cancer Survivors Month in Canada,…

Read More >

PURDUE PHARMA (CANADA) APPOINTS ANDRÉ CÔTÉ VICE PRESIDENT, HEALTH SOLUTIONS

Published on - May 22, 2018

PICKERING, ON, May 22, 2018 /CNW/ — André Côté is appointed Vice President, Health Solutions…

Read More >

A Message from the Purdue Pharma (Canada) Leadership Team

Published on - May 8, 2018

While prescription opioid medicines remain a safe and effective treatment for patients who are appropriately…

Read More >

Purdue Pharma (Canada) appoints Melanie Milburn Vice President of Marketing

Published on - May 2, 2018

PICKERING, ON, May 2, 2018 – Melanie Milburn is appointed Vice President Marketing after successfully…

Read More >

National Cancer Awareness Month – Message from Dr. Tom Koutsavlis, Vice-President, Research & Development, Purdue Pharma (Canada)

Published on - April 11, 2018

April is Cancer Awareness Month. According to the Canadian Cancer Society, cancer is the leading…

Read More >

PENTHROX® RECEIVES MARKETING AUTHORIZATION FROM HEALTH CANADA FOR ADULT PATIENTS REQUIRING RELIEF FROM MODERATE TO SEVERE ACUTE PAIN ASSOCIATED WITH TRAUMA OR INTERVENTIONAL MEDICAL PROCEDURES

Published on - April 10, 2018

Pickering, ON (Canada) (April 10, 2018): Purdue Pharma (Canada) and Medical Developments International Limited (MDI),…

Read More >

NEW TREATMENT OPTION FOR ADULTS WITH ADHD: FOQUEST™ (METHYLPHENIDATE CONTROLLED RELEASE CAPSULES) NOW AVAILABLE IN CANADA

Published on - February 1, 2018

First and only methylphenidate product approved in Canada with a 16-hour duration of action PICKERING,…

Read More >

BELBUCA® – A NEW TREATMENT OPTION FOR CANADIANS LIVING WITH CHRONIC PAIN – NOW AVAILABLE IN CANADA

Published on - January 30, 2018

Pickering, ON (Canada) (January 30, 2018): Purdue Pharma (Canada) and BioDelivery Sciences International Inc. (BDSI)…

Read More >
↓